Clinical trials: Metastatic Solid Tumor Cancer
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003331
- Testing
- fluorouracil, leucovorin calcium, topotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors
Study Purpose and Design:A Multicenter, Open-label, Exploratory Phase II Clinical Study to Evaluate the Safety and Tolerability and Preliminary Efficacy of TJ107 in Combination with Pembrolizumab Injection in Patients with…
- Trial name
- NCT05145907
- Testing
- TJ107 +Pembrolizumab
- Where
- 20 sites in China
- Volunteers
- 133 people
- Sponsor
- TJ Biopharma Co., Ltd.
Advanced Solid Tumors Cancer
A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of…
- Trial name
- NCT03145909
- Testing
- ABBV-176
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 19 people
- Sponsor
- AbbVie
Extradural Tumor, Spinal Metastases
SBRT in the Management of Solid Spinal Metastases
Documenting efficiency of SBRT in the management of epidural spinal metastases from solid tumors
- Trial name
- NCT04863612
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Advanced or Metastatic Solid Tumors
A Phase 1 Study to Evaluate TGI-6 in Subjects With Locally Advanced/Metastatic Solid Tumors
A Phase 1 Study to Evaluate TGI-6 in Subjects with Locally Advanced/Metastatic Solid Tumors
- Trial name
- NCT06374173
- Testing
- TGI-6 Injection
- Where
- China
- Volunteers
- 123 people
- Sponsor
- Hefei TG ImmunoPharma Co., Ltd.
Metastatic Cancer, Pain
Morphine After Radiofrequency Ablation of Painful Bone Metastases in Patients With Cancer
RATIONALE: Morphine may reduce pain in patients who have undergone radiofrequency ablation to remove bone metastases. PURPOSE: This phase II trial is studying how well morphine works after radiofrequency ablation of painful bone…
- Conditions
- Metastatic Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- MEDOR (NCT00712712)
- Testing
- Acetaminophen, Morphine Sulfate, Questionnaire administration
- Where
- France
- Volunteers
- 78 people
- Sponsor
- Institut Bergonié
Carcinoma, Non-Small Cell, Neoplasm Metastasis
A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks
This study will explore the combination of the oral drug PF-00299804 and intravenous CP-751,871 in patients with advanced solid tumor.
- Trial name
- NCT00728390
- Testing
- PF-00299804
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 74 people
- Sponsor
- Pfizer
Advanced Solid Tumor, Metastatic Breast Cancer
ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer
This study evaluates the anti-tumor effects of ORIN 1001 in patients with advanced solid tumors or relapsed refractory metastatic breast cancer (patients with progressive disease after receiving at least two lines of therapy in…
- Trial name
- NCT03950570
- Testing
- Abraxane, ORIN1001
- Where
- 20 sites in United States
- Volunteers
- 58 people
- Sponsor
- Orinove, Inc.
Solid Tumor
Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion
AB-106 will be administered once a day. Each treatment cycle is defined as 21 days of continuous medication. Dosing will continue until any of the following conditions are met: disease progression, intolerable drug-related…
- Trial name
- NCT04617054
- Testing
- AB-106
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Nuvation Bio Inc.
Locally Advanced, Recurrent or Metastatic Malignancies
SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors
This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Monotherapy and Combination Therapy in patients with advanced HER2-Expressing Solid Tumors.
- Trial name
- NCT07022002
- Testing
- SSGJ-705, PD-1/L1 inhibitor combined with chemotherapy, SSGJ-705 combined with chemotherapy
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Brain and Central Nervous System Tumors, Cognitive/Functional Effects
Ph I Study of Lithium During Whole Brain Radiotherapy For Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs, such as lithium, may protect normal cells from the side effects of radiation therapy.
- Conditions
- Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Neurotoxicity, Solid Tumor
- Trial name
- NCT00469937
- Testing
- lithium carbonate, cognitive assessment, quality-of-life assessment
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Locally Advanced Solid Tumor, Metastatic Solid Tumor
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JBI-802 in patients with Advanced Solid Tumors.The efficacy of the RP2D will be evaluated in phase 2 in patients…
- Trial name
- NCT05268666
- Testing
- JBI-802
- Where
- 4 sites in United States
- Volunteers
- 126 people
- Sponsor
- Jubilant Therapeutics Inc.
Solid Tumor, Stomach Cancer
Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer
Alpelisib (BYL719) is a PIK3CA-specific inhibitor, which was developed by Novartis (Basel, Switzerland). Our group conducted pre-clinical study of alpelisib in eight gastric cancer cell lines: four PIK3CA wild-type (SNU638…
- Trial name
- NCT04526470
- Testing
- Alpelisib, Paclitaxel
- Where
- 2 sites in South Korea
- Volunteers
- 55 people
- Sponsor
- Seoul National University Bundang Hospital
Malignant Neoplasm of Nasopharynx TNM Staging Distant Metastasis (M), Breast Cancer Recurrent
EpCAM CAR-T for Treatment of Advanced Solid Tumors
This study is for patients that have nasopharyngeal carcinoma, breast cancer, gastric cancer and other solid tumors. As epithelial cell adhesion molecule (EpCAM) is a well characterized molecule that is closely with poor…
- Conditions
- Malignant Neoplasm of Nasopharynx TNM Staging Distant Metastasis (M), Breast Cancer Recurrent, Gastric Cancer With Metastasis
- Trial name
- NCT02915445
- Testing
- EpCAM CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan University
Advanced/Metastatic Solid Malignancies
IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
The study is to evaluate preliminary anti-tumor activity (overall response rate, ORR) of IBI308 monotherapy in subjects with advanced/metastatic solid malignancies.
- Trial name
- NCT03568539
- Testing
- IBI308
- Where
- 7 sites in United States
- Volunteers
- 39 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Advanced Malignant Solid Tumors
A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RCZY690 in Advanced Solid Tumors
This study aims to evaluate the safety and efficacy of RCZY690 therapy in participants with advanced malignant solid tumors. Participants will receive RCZY690 monotherapy until the end of the study.
- Trial name
- NCT07806175
- Testing
- RCZY690 Tablets, RCZY690 tables
- Where
- 8 sites in China
- Volunteers
- 486 people
- Sponsor
- Rongchang Pharmaceuticals Co., Ltd.
Advanced Solid Tumors
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer
This is an open-label study, in participants with advanced and/or metastatic solid tumors, which consists of 2 parts: a research phase (inpatient) and a treatment phase.
- Trial name
- NCT03991494
- Testing
- [14C]-pamiparib
- Where
- 2 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- BeiGene
Metastatic Melanoma, Refractory Malignant Solid Neoplasm
Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies
This phase I trial studies the side effects and best dose of cediranib maleate and selumetinib sulfate in treating patients with solid malignancies.
- Conditions
- Metastatic Melanoma, Refractory Malignant Solid Neoplasm, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT01364051
- Testing
- Cediranib, Cediranib Maleate, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic or Locally Advanced Unresectable Solid Tumors
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
This is an open-label, Phase I, first-in-human (FIH) multicenter, clinical study conducted in multiple parts to establish the safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) profile (with and without food) and…
- Trial name
- NCT04170153
- Testing
- M1774, Niraparib
- Where
- 16 sites in United States, China and 3 more
- Volunteers
- 161 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
RAS Mutation, Advanced Solid Tumor
A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations
The purpose of this study is to test if the BG-85738 is safe and if it works in patients with advanced solid tumors with RAS mutations when it is given on its own and in combination.
- Conditions
- RAS Mutation, Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT07746141
- Testing
- BG-85738, Tislelizumab, Cetuximab
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 100 people
- Sponsor
- BeOne Medicines
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.